Dermatologic reactions were commonly seen in CHRYSALIS trial with 86% of patients experiencing rash of any grade, including dermatitis acneiform, which is one of the most common on-target dermatological AEs associated with EGFR inhibitors. This evidence concerns the gene EGFR and acneiform dermatitis.